Are cannabinoids effective for orofacial pain states?

Journal of Oral and Facial Pain and Headache

Volumn 29, Issue 1, 2015, Pages 5-6

  Sessle, Barry J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CANNABINOID;

CHRONIC PAIN; HUMAN; NEURALGIA;

ANALGESICS; CANNABINOIDS; CHRONIC PAIN; HUMANS; NEURALGIA;

EID: 84925283846     PISSN: 23330384     EISSN: 23330376     Source Type: Journal    
DOI: 10.11607/ofph.2015.1.e     Document Type: Editorial

References (7)

1. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009;6:713-737.
2. Fine PG, Rosenfeld MJ. Cannabinoids for neuropathic pain. Curr Pain Headache Rep 2014;18:451.
3. McDonough P, McKenna JP, McCreary C, Downer EJ. Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 2014;21;55C:72-78.
4. Liang YC, Huang CC, Hsu KS. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacol 2007;53:169-177.
5. Papanastassiou AM, Fields HL, Meng ID. Local application of the cannabinoid receptor agonist, WIN 55, 212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons. Pain 2004;107:267-275.
6. Burgos E, Pascual D, Martín MI, Goicoechea C. Antinociceptive effect of the cannabinoid agonist, WIN 55, 212-2, in the orofacial and temporomandibular formalin tests. Eur J Pain 2010;14:40-48.
7. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: Implications in migraine. J Neurosci 2013;33:14869-14877.